
satellos
REGENERATING MUSCLE FROM WITHIN™

Legal Disclaimers

Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always using words or phrases such as “expect”, “seek”, “endeavor”, “anticipate”, “plan”, “estimate”, “believe”, “intend”, or stating that certain actions, events or results may, could, would, might or will occur or be taken, or achieved) are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which would cause actual results or events to differ materially from those presently anticipated. Forward-looking statements are based on expectations, estimates and projections at the time the statements are made and involve significant known and unknown risks, uncertainties and assumptions. A number of factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. These include, but are not limited to, risks regarding the pharmaceutical industry, market conditions, economic factors, management’s ability to manage and operate the business of Satellos and the equity markets generally. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements could vary materially from those expressed or implied by the forward-looking statements contained in this document. These factors should be considered carefully. Existing or prospective investors should not place undue reliance on these forward-looking statements. Although the forward-looking statements contained in this document are based upon what Satellos Bioscience Inc. (“Satellos”) currently believes to be reasonable assumptions, Satellos cannot assure recipients that actual results, performance or achievements will be consistent with these forward-looking statements. Except as required by law, Satellos does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances.

This presentation is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. Investors should consult with their own professional advisors regarding their particular circumstances.

The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The public disclosure records of Satellos are expressly not incorporated by reference into this presentation. Satellos disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. The industry data, forecasts and other information prepared by third parties presented in this presentation, except where otherwise noted, has been compiled from industry sources and participants which, although not independently verified by Satellos, are considered by Satellos to be reliable sources of information. References in this presentation to reports or articles should not be construed as depicting the complete findings of the entire referenced report or article and such report or article is expressly not incorporated by reference into this presentation. Satellos makes no representation or warranty as to the accuracy or completeness of any data or information prepared by third parties included in this presentation and Satellos assumes no liability whatsoever relating to or resulting from such data or information or the use thereof, errors therein or omissions therefrom.

Satellos: A New Chapter in Treating Muscle Diseases with SAT-3247

- Disruptive science
- Novel approach with potential to be disease modifying
- Well tolerated, easy-to-administer medication
- Areas of enormous unmet need

Corporate Highlights

1.	2.	3.	4.	5.
Clinical stage company	**Strong balance sheet**	**Upcoming flow of milestones**	**Accomplished leadership team**	**Elite institutional investors**

Grounded in science. Inspired by need.

Our mission is to improve the treatment of Duchenne muscular dystrophy and other devastating muscle diseases by restoring the body's ability to regenerate muscle.

CHARLIE, age 7,
living with Duchenne

SAT-3247 is Totally Different: Not Just Stabilizing — Regenerating

Genetic approaches

- Administered by infusion or injection
- Gene therapy (DNA) or exon skipping (RNA)
- Aims to slow disease progression by stabilizing muscle
- Limited by exon status or potential immunogenicity concerns

WAVE LIFE SCIENCES
AVIDITY BIOSCIENCES
Dyne THERAPEUTICS
SAREPTA THERAPEUTICS
SOLID BIOSCIENCES

Satellos's approach

- Oral, once-daily pill
- Designed to be safe and tolerable
- Aims to reverse disease progression by regenerating muscle
- Intended for all patients regardless of exon or immune status
- Novel mechanism with potential as stand-alone or add-on therapy

SAT-3247 Restores Muscle Strength in Canine Model of DMD to Normative Levels

Satellos Canine Study

- 4-month study
- 2 dogs ~9 months of age to ~13 months
- Retriever cross with natural DMD mutation
- Oral daily dosing with SAT-3247 (4x/week)
- Strength at 2 and 4 months

SAT-3247 treated vs. historical controls



Contraction force generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophy

Joe N. Kornegay[a,b,*] Daniel J. Bogan[a,b], Janet R. Bogan[a,b], Martin K. Childers[b,c], Diane D. Cundiff[a,b], Gregory F. Petroski[d], Ronald O. Schueler[a,b]

[a]Department of Veterinary Medicine and Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA
[b]Dalton Cardiovascular Research Center, University of Missouri, Columbia, MO 65211, USA
[c]Department of Physical Medicine and Rehabilitation, School of Medicine, University of Missouri, Columbia, MO 65211, USA
[d]Department of Biostatistics, School of Medicine, University of Missouri, Columbia, MO 65211, USA

SAT-3247 Restores Muscle Strength in Murine Model of FSHD to Near Normative Levels

Satellos FSHD Canada Joint Study

- 3-month study
- FLExDux4 mouse model of FSHD
- Oral daily dosing with SAT-3247 (4x/week)
- Strength at 4, 8, 12 weeks post administration

SAT-3247 vs placebo vs healthy animals



Advancing SAT-3247 into Clinical Development

SAT-3247 Phase 1 First-in-Human Clinical Study

Healthy Volunteers (n=72)			Adults with DMD
SAD	MAD	Crossover Food Effect	Multiple Dosing
▪ 10 - 400 mg ▪ 5 cohorts of 8 ▪ Single dose / 1 day	▪ 60 - 240 mg ▪ 5 cohorts of 8 ▪ Single dose / 7 days	▪ 150 mg ▪ 1 cohort of 8 ▪ Single dose / 1 day	▪ 60 mg ▪ 1 cohort of up to 10 ▪ Single dose for 5 consecutive weekdays 4 wks
Complete			Ongoing

Endpoints

Primary: Safety & tolerability

Secondary: Pharmacokinetics (NB., DMD adults also receiving their prescribed steroid treatment)

Exploratory*: Grip strength, 99th maximum effort, forced vital capacity, serum markers

*SAD: single ascending dose; MAD: multiple ascending dose; *adults with DMD*

SAT-3247 Appears Safe and Tolerable in Healthy Volunteer Study[1]

Single Ascending Dose

No clinically significant findings observed in 10, 50, 150, 300 and 400 mg doses.

- ☑ Labs
- ☑ Vitals
- ☑ Physical Exam
- ☑ ECG

Drug-related adverse events, reversible:

- **400 mg:** mild nausea (1); mild abdominal pain (1)

Multiple Ascending Dose

No clinically significant findings observed in **60**, **120**, 180, 240 mg doses:

- ☑ Labs (mild transaminase elevations at 180 and 240 mg)
- ☑ Vitals
- ☑ Physical Exam
- ☑ ECG

Drug-related adverse events, reversible:

- **120 mg:** mild lightheadedness (1)
- **180 mg:** intermittent mild epigastric pain (1); mild sleepiness (1); mild lethargy (1)

[1] *Based on 20 Feb 2025 data cut-off; study is ongoing*

Clinical Program Overview

2025				2026			
Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4

Phase 1 Program (Underway: Australia)

Ph 1a
72 HVs
SAD/MAD/FE

Data Presented at MDA/2025

Ph 1b
Up to 10 Adult DMD Patients
Safety + PK | 28 day

Q2 Data Reporting

Ph 1b
Long-Term Follow-up | 11 Months of Dosing
Safety | Pharmacodynamics

Ongoing Reporting

DMD Phase 2 Program (Planned: USA, Canada, AUS, EU)

Regulatory Filing/s

Ph 2 Clinical Trial Program
Randomized, Placebo Controlled Studies in DMD Patients in Multiple Jurisdictions
Safety & Proof-of-Concept | Muscle Function, Muscle Imaging, Serum & Histology Biomarkers

Ph 2 Clinical Program Designed to Produce Data Readouts at Pre-Defined Intervals

Inside Satellos

Our company and the team leading it forward

Satellos Has Built a World-Caliber Team

Frank Gleeson, MBA
Co-Founder & Chief Executive Officer

Michael Rudnicki, OC, PhD, FRS
Co-Founder & Chief Discovery Officer

Liz Williams, CPA, CA
Chief Financial Officer

Courtney Wells
SVP – Clinical Development Operations

Philip Lambert, PhD
Chief Scientific Officer

Ryan Mitchell, PhD
SVP – Medical & Scientific Affairs

Clinical Advisory Board

Jordan Dubow, MD
Chair, CAB and Chief Medical Officer, Satellos Bioscience

Nicholas Johnson, MD, MSCI, FAAN
Division Chief of Neuromuscular, Virginia Commonwealth University

Hanns Lochmüller, MD, PhD
Senior Scientist, Children's Hospital of Eastern Ontario Research Institute

Richard Finkel, MD
Director, Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital

Francesco Muntoni, MD, PhD
Director, Dubowitz Neuromuscular Centre, Great Ormond Street UCL Institute of Child Health

Perry Shieh, MD, PhD, FAAN
Professor of Neurology, UCLA David Geffen School of Medicine

Ronald Cohn, MD, PhD
President and CEO, Hospital for Sick Children, Toronto

Reimagine

how muscle degeneration is treated.

Regenerate

with small molecule medicines.

Realize

the next horizon to improve lives.